155 related articles for article (PubMed ID: 14575844)
1. How low is the alpha/beta ratio for prostate cancer?
Kal HB; Van Gellekom MP
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1116-21. PubMed ID: 14575844
[TBL] [Abstract][Full Text] [Related]
2. Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema.
Van Gellekom MP; Moerland MA; Kal HB; Battermann JJ
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):422-33. PubMed ID: 12023147
[TBL] [Abstract][Full Text] [Related]
3. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
4. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives.
Chen Z; Nath R
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):825-34. PubMed ID: 12573770
[TBL] [Abstract][Full Text] [Related]
5. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
6. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
[TBL] [Abstract][Full Text] [Related]
7. How low is the alpha/beta ratio for prostate cancer?
Wang JZ; Guerrero M; Li XA
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054
[TBL] [Abstract][Full Text] [Related]
8. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?
Wang JZ; Li XA; Yu CX; DiBiase SJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
[TBL] [Abstract][Full Text] [Related]
9. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
10. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
11. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
[TBL] [Abstract][Full Text] [Related]
12. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
[TBL] [Abstract][Full Text] [Related]
13. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
[TBL] [Abstract][Full Text] [Related]
14. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
15. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
16. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
17. Determination of the prescription dose for biradionuclide permanent prostate brachytherapy.
Nuttens VE; Lucas S
Med Phys; 2008 Dec; 35(12):5451-62. PubMed ID: 19175105
[TBL] [Abstract][Full Text] [Related]
18. Calculating prescription doses for new sources by biologically effective dose matching.
Pritz J; Forster KM; Saini AS; Biagioli MC; Zhang GG
Brachytherapy; 2012; 11(6):521-7. PubMed ID: 22436519
[TBL] [Abstract][Full Text] [Related]
19. Is alpha/beta for prostate tumors really low?
Fowler J; Chappell R; Ritter M
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1021-31. PubMed ID: 11429230
[TBL] [Abstract][Full Text] [Related]
20. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
